Apollon Formularies plc (APOL) ORD NPV
- Add to watchlist
- This stock can be held in a
Business summary
Apollon Formularies plc is a United Kingdom-based medical cannabis pharmaceutical company. The Company is engaged in specializing in research and treatment of patients with cancer and chronic pain. The Company has hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products. Its products with trademarks include APOLLON-Full Extract Cannabis Oil (FECO) Vape, APOLLON FECO Oral Tincture-30ml Bottle, and APOLLON FECO Prescribed Capsules. It also includes Apollon NAUSEA Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER. It offers services, including cultivation, processing and extraction, international cancer institute, retail product sales, Apollon Negril facility, research and development, and bespoke treatments and products. The Company’s wholly owned subsidiary is Apollon Formularies Ltd.
Contact details
Important dates
General stock information
- EPIC:
- APOL
- ISIN:
- IM00BJ0LRD77
- Market cap:
- £749,730
- Shares in issue:
- 771.19 million
- Sector:
- Pharmaceuticals
- Exchange:
- -
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.